高剂量拓扑替康（90 μG和180 μG）治疗视网膜母细胞瘤复发性视网膜下和玻璃体植入

Q3 Medicine

American Journal of Ophthalmology Case Reports Pub Date : 2025-09-17 DOI:10.1016/j.ajoc.2025.102437

David H. Abramson , Jasmine H. Francis

{"title":"高剂量拓扑替康（90 μG和180 μG）治疗视网膜母细胞瘤复发性视网膜下和玻璃体植入","authors":"David H. Abramson , Jasmine H. Francis","doi":"10.1016/j.ajoc.2025.102437","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To report on the use of intravitreal high-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous retinoblastoma, the toxicity of these injections, and the use of a 180-μG injection of intravitreal topotecan in humans.</div></div><div><h3>Observations</h3><div>High-dose (90 and 180 μG) intravitreal topotecan was effective in treating recurrent subretinal and vitreous retinoblastoma without anterior segment or retinal toxicity or altered electroretinogram function in two cases.</div></div><div><h3>Conclusion and importance</h3><div>Recurrent subretinal and vitreous retinoblastoma after intraarterial chemotherapy are difficult to treat. High-dose intravitreal topotecan (90 and 180 μG) was used to salvage two such eyes without measurable toxicity.</div></div>","PeriodicalId":7569,"journal":{"name":"American Journal of Ophthalmology Case Reports","volume":"40 ","pages":"Article 102437"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"High-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous seeding in retinoblastoma\",\"authors\":\"David H. Abramson , Jasmine H. Francis\",\"doi\":\"10.1016/j.ajoc.2025.102437\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>To report on the use of intravitreal high-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous retinoblastoma, the toxicity of these injections, and the use of a 180-μG injection of intravitreal topotecan in humans.</div></div><div><h3>Observations</h3><div>High-dose (90 and 180 μG) intravitreal topotecan was effective in treating recurrent subretinal and vitreous retinoblastoma without anterior segment or retinal toxicity or altered electroretinogram function in two cases.</div></div><div><h3>Conclusion and importance</h3><div>Recurrent subretinal and vitreous retinoblastoma after intraarterial chemotherapy are difficult to treat. High-dose intravitreal topotecan (90 and 180 μG) was used to salvage two such eyes without measurable toxicity.</div></div>\",\"PeriodicalId\":7569,\"journal\":{\"name\":\"American Journal of Ophthalmology Case Reports\",\"volume\":\"40 \",\"pages\":\"Article 102437\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Ophthalmology Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2451993625001902\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Ophthalmology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451993625001902","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的报道玻璃体内注射高剂量拓扑替康（90 μG和180 μG）治疗复发性视网膜下和玻璃体视网膜母细胞瘤的疗效、毒性及玻璃体内注射180 μG拓扑替康的临床应用。观察高剂量（90 μG和180 μG）拓扑替康治疗复发性视网膜下和玻璃体视网膜母细胞瘤2例，无前段视网膜毒性和视网膜电图功能改变。结论及重要性动脉化疗后复发的视网膜下、玻璃体视网膜母细胞瘤治疗困难。玻璃体内注射高剂量拓扑替康（90 μG和180 μG）抢救两只眼，无明显毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

High-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous seeding in retinoblastoma

Purpose

To report on the use of intravitreal high-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous retinoblastoma, the toxicity of these injections, and the use of a 180-μG injection of intravitreal topotecan in humans.

Observations

High-dose (90 and 180 μG) intravitreal topotecan was effective in treating recurrent subretinal and vitreous retinoblastoma without anterior segment or retinal toxicity or altered electroretinogram function in two cases.

Conclusion and importance

Recurrent subretinal and vitreous retinoblastoma after intraarterial chemotherapy are difficult to treat. High-dose intravitreal topotecan (90 and 180 μG) was used to salvage two such eyes without measurable toxicity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Ophthalmology Case Reports Medicine-Ophthalmology

CiteScore

2.40

自引率

0.00%

发文量

513

审稿时长

16 weeks

期刊介绍： The American Journal of Ophthalmology Case Reports is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished case report manuscripts directed to ophthalmologists and visual science specialists. The cases shall be challenging and stimulating but shall also be presented in an educational format to engage the readers as if they are working alongside with the caring clinician scientists to manage the patients. Submissions shall be clear, concise, and well-documented reports. Brief reports and case series submissions on specific themes are also very welcome.